Riddell, Michael C.2019-03-052019-03-052018-12-142019-03-05http://hdl.handle.net/10315/35907Sodium glucose co-transporter 2 inhibitors (SGLT2i) have begun to show promise as an add-on to insulin therapy in patients with type 1 diabetes (T1D), however the effects of these drugs on plasma glucagon concentrations in T1D are not yet known. We investigated whether 8 days of SGLT2i treatment altered plasma glucagon concentrations in response to voluntary physical activity and insulin-induced hypoglycemia in male and female rats with streptozotocin-induced T1D. SGLT2 inhibition did not alter basal or post-exercise glucagon concentrations and did not affect exercise-associated changes in blood glucose levels. Additionally, SGLT2 inhibition did not affect voluntary running distance. However, in males, SGLT2 inhibition appeared to have suppressed the glucagon response to insulin-induced hypoglycemia (+40.4 48.6 pg/mL vs +22.7 30.8 pg/mL, p=0.02) and decreased the time to taken to reach hypoglycemia (63.8 17.2 min vs 30 13.4 min, p<0.0001). These results have potentially concerning implications for the use of SGLT2i in the treatment of T1D.enAuthor owns copyright, except where explicitly noted. Please contact the author directly with licensing requests.KinesiologyElectronic Thesis or Dissertation2019-03-05Type 1 diabetesSGLT2ExerciseHypoglycemiaBlood glucoseSGLT2 inhibitorRunning wheelRodents--RatsStreptozotocinstzInsulinGlucagon